Table 1 Baseline characteristics.
From: Adverse kidney outcomes of CDK 4/6 inhibitors for metastatic breast cancer
Covariates | Abemaciclib, N = 153 | Palbociclib, N = 238 | Ribociclib, N = 10 | Aromatase inhibitors, N = 73 |
|---|---|---|---|---|
Age | 59 (13) | 62 (13) | 53 (9) | 59 (14.49) |
Female sex | 153 (100%) | 238 (100%) | 10 (100%) | 73 (100%) |
Race | ||||
White | 130 (85.0%) | 199 (83.6%) | 9 (90%) | 67 (91.8%) |
Asian | 7 (4.6%) | 12 (5.0%) | 0 (0%) | 1 (1.4%) |
Black | 8 (5.2%) | 10 (4.2%) | 0 (0%) | 2 (2.7%) |
Hispanic | 0 (0%) | 2 (0.8%) | 0 (0%) | 0 (0%) |
Other/not recorded | 8 (5.2%) | 15 (6.3%) | 1 (10%) | 3 (4.1%) |
Median baseline eGFR (mL/min/1.73 m2) | 93 [77, 105] | 90 [74, 101] | 98 [92, 107] | 88 [74, 104] |
Comorbidities | ||||
Hypertension | 72 (47.1%) | 126 (52.9%) | 5 (50%) | 18 (24.7%) |
Coronary artery disease | 23 (15.0%) | 34 (14.3%) | 1 (10%) | 4 (5.5%) |
Diabetes mellitus | 31 (20.3%) | 41 (17.2%) | 1 (10%) | 8 (11.0%) |
Cirrhosis | 3 (2.0%) | 1 (0.4%) | 0 (0%) | 1 (1.4%) |
Medication use | ||||
Diuretics | 48 (31.4%) | 64 (26.9%) | 2 (20%) | 12 (16.4%) |
ACEi/ARB | 32 (20.9%) | 63 (26.5%) | 1 (10%) | 8 (11.0%) |
Proton Pump Inhibitors | 74 (48.4%) | 93 (39.1%) | 4 (40%) | 14 (19.2%) |
